Empfehlungen für die Auswahl von Inhalationssystemen zur Medikamentenverabreichung

 

 Permissions and Reprints

Die inhalative Applikation von Medikamenten ist die bedeutsamste Form der Behandlung von obstruktiven Atemwegserkrankungen [30] [75] [99]. Gründe hierfür sind die hohe lokale Wirkstoffkonzentration bei geringer Gesamtdosis und das damit verbundene günstige Wirkungs-/Nebenwirkungsverhältnis (z. B. Glukokortikoide) sowie der rasche Wirkungseintritt (z. B. Beta-2-Adrenergika) [2] [73] [113] [114]. Neben Medikamenten zur topischen Therapie wird zunehmend die Inhalation verschiedener Substanzen zur systemischen Behandlung geprüft [17] [19] [59] [60] [65] [93]. Darüber hinaus werden neue Applikationssysteme entwickelt [93]. Die große Auswahl von Inhalationssystemen führt nicht selten zu einer Unsicherheit bei Ärzten und Patienten, obgleich sie die Möglichkeit bietet, für jeden individuellen Fall ein geeignetes System auszuwählen. Hierfür ist die Kenntnis einiger Grundsätze der Aerosolmedizin und technologischer Aspekte der Inhalationsbehandlung erforderlich.

Ziel jeder Inhalationstherapie muss es sein, dem Patienten ein System zur Verfügung zu stellen, das einfach zu handhaben ist, eine hohe Dosiskonstanz und eine optimale Deposition im gewünschten Bereich des Atemtraktes ermöglicht [8] [13] [95].

Literatur

• 1 Ad Hoc Committee on Health Literacy for the Council of Scientific Affairs, American Medical Association, Health Literacy . Report of the Council of Scientific Affairs.  JAMA. 1999;  281 552-557
  CrossrefPubMedGoogle Scholar
• 2 Aerosol Consensus Statement . Chest. 1991;  100 1106-1109
  PubMed
• 3 Alvine G F, Rodgers P, Fitzsimmons K M, Ahrens R C. Disposable jet nebulisers. How reliable are they?.  Chest. 1992;  101 316-319
  PubMedGoogle Scholar
• 4 Armitage J M, Williams S J. Inhaler technique in the elderly.  Age and Ageing. 1988;  17 275-278
  PubMedGoogle Scholar
• 5 Barry P, O'Callaghan C. Multiple actuations of salbutamol MDI into a spacer device reduce the amount of drug recovered in the respirable range.  Eur Respir J. 1994;  7 1707-1709
  CrossrefPubMedGoogle Scholar
• 6 Barry P, O'Callaghan C. Poor output of salbutamol from a spacer device - the effect of spacer static charge and multiple actuations.  Thorax. 1994;  49 402
  PubMedGoogle Scholar
• 7 van Beerendonk I, Mesters I, Mudde A N, Tan T D. Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device.  J Asthma. 1998;  35 273-279
  CrossrefPubMedGoogle Scholar
• 8 Boe J, Dennis J H. European respiratory society nebulizer guidelines: technical aspects.  Eur Respir Rev. 2000;  10 (Rev. 72) 1-237
  PubMedGoogle Scholar
• 9 Borgström L, Asking L, Beckman O, Bondesson E, Källén A, Olsson B. Discrepancy between in vitro and in vivo dose variability for a pressurized metered dose inhaler and a dry powder inhaler.  J Aersosol Med. 1998;  11 (Suppl. 1) 59-64
  PubMedGoogle Scholar
• 10 Braunstein G L, Trinquet G, Harper A E. Compliance with nedocromil sodium and a nedocromil sodium/salbutamol combination.  Eur Respir J. 1996;  9 893-898
  CrossrefPubMedGoogle Scholar
• 11 Brenner M. Use of steroids in pediatric asthma.  Pediatr Ann. 1989;  18 810 - 813, 816-818 (Review)
  PubMedGoogle Scholar
• 12 Brindley A, Sumby B S, Smith I J, Prime D. et al . Design, manufacture and dose consistancy of the serevent diskus inhaler.  Pharm Tech Eur. 1995;  1 14-22
  PubMedGoogle Scholar
• 13 British Thoracic Society, National Asthma Campaign, Royal College of Physicians of London et al . The British guidelines on asthma management: 1995 review and position statement.  Thorax. 1997;  22 (Suppl. 1) S11
  PubMedGoogle Scholar
• 14 Brown P H, Ning A CWS, Greening A P, McLean A, Crompton G K. Peak inspiratory flow through Turbohaler® in acute asthma.  Eur Respir J. 1995;  8 1940-1941
  CrossrefPubMedGoogle Scholar
• 15 Brown P H, Blundell G, Greening A P, Crompton G K. Do large spacer devices reduce the systemic effects of high dose inhaled corticosteroids?.  Thorax. 1990;  45 736-739
  PubMedGoogle Scholar
• 16 Bundesinstitut für Arzneimittel und Medizinprodukte . Bekanntmachung über die Zulassung und Registrierung sowie die Verlängerung der Zulassung von Arzneimitteln - Ausnahmen vom Verbot bestimmter die Ozonschicht abbauender Halogenkohlenwasserstoffe nach der FCKW-Halon-Verbots-Verordnung.  Bundesanzeiger. 2000;  4 141
  PubMedGoogle Scholar
• 17 Byron P R. Pulmonary targeting with aerosols.  Pharm Technol. 1987;  5 42-54
  PubMedGoogle Scholar
• 18 Byron P R, Peart J, Staniforth J N. Aerosol electrostatics. I: Properties of fine powders before and after aerosolization by dry powder inhalers.  Pharm Res. 1997;  14 698-705
  CrossrefPubMedGoogle Scholar
• 19 Byron P R, Patton J S. Drug delivery via the respiratory tract.  J Aerosol Med. 1994;  7 49-75
  PubMedGoogle Scholar
• 20 Chinn S, Arossa W A, Jarvis D L, Luczynska C M, Burney P G. Variation in nebulizer aerosol output and weight output from the Mefar disometer: implications for multicentre studies.  Eur Respir J. 1997;  10 452-456
  CrossrefPubMedGoogle Scholar
• 21 Clark A R, Hollingworth A M. The relationship between powder inhaler resistance and peak inspiratory conditions in healthy human volunteers - implications for in vitro testing.  J Aerosol Sci. 1993;  6 99-110
  PubMedGoogle Scholar
• 22 Cochrane G M, Horne R, Chanez P. Compliance in asthma.  Respir Med. 1999;  93 763-769
  CrossrefPubMedGoogle Scholar
• 23 Cochrane G M, Bala M V, Downs K E, Mauskopf J, Ben-Joseph R H. Inhaled corticosteroids for asthma therapy. Patients compliance, devices, and inhalation technique.  Chest. 2000;  117 542-550
  CrossrefPubMedGoogle Scholar
• 24 Crompton G K. Dry powder inhalers: advantages and limitations.  J Aerosol Med. 1991;  3 151-156
  PubMedGoogle Scholar
• 25 Crompton G. Problems patients have using pressurized aerosol inhalers.  Eur J Respir Dis. 1982;  63 (Suppl. 119) 101-104
  PubMedGoogle Scholar
• 26 Dalby R N, Tiano S L, Hickey A J. Medical devices for the delivery of therapeutic aerosols to the lung. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 441-474
  Google Scholar
• 27 Davadason S G, Everard M L, Linto J M, Le Souef P N. Comparison of drug delivery from conventional versus Venturi 1/2 nebulizers.  Eur Respir J. 1997;  10 2479-2483
  CrossrefPubMedGoogle Scholar
• 28 Dekhuijsen P NR. Inhalatiemedicatie bij volwassenen met obstructieve longaandoeningen: poeder of aërosol?.  Ned Tijdschr Gneeskd. 1998;  141 1369-1374
  PubMedGoogle Scholar
• 29 Dennis J H. Drug nebulizer design and performance: Breath enhanced jet vs. constant output jet vs. ultrasonic.  J Aerosol Med. 1995;  8 277-280
  PubMedGoogle Scholar
• 30 Dennis J H, Hendrick D J. Design characteristics for drug nebulizers.  J Med Eng Technol. 1992;  16 63-68
  PubMedGoogle Scholar
• 31 Deutsche Atemwegsliga . Inhalationstherapie bei obstruktiven Atemwegserkrankungen.  Pneumologie. 1994;  48 338-341
  PubMedGoogle Scholar
• 32 Deutsche Atemwegsliga . Positionspapier zu Treibgasen in Dosieraerosolen.  Med Klinik. 1995;  90 617 (Nr. 11)
  PubMedGoogle Scholar
• 33 Dewsbury N J, Kenyon C J, Newman S P. The effect of handling techniques on electrostatic charge on spacer devices: a correlation with in vivo particle size analysis.  Int J Parm. 1996;  137 216-264
  PubMedGoogle Scholar
• 34 Egermann H. Mischen von Feststoffen. In: Hagers Handbuch der pharmazeutischen Praxis, Band 2: Methoden Berlin: Springer Verlag 1991
  Google Scholar
• 35 Everard M L, Dolovich M. In vivo measurements of lung dose. In: Risgaard M, O'Callaghan C, Smaldone G (Hrsg). Drug delivery in the lung: clinical aspects. Lung biology in health and disease New York: Marcel Dekker 2000: (in press)
  Google Scholar
• 36 Farrer M, Francis A J, Pearce S J. Monitoring serum cortisol concentration after 2 mg inhaled beclomethasone dipropionate in normal subjects: effect of a 750 ml spacing device.  Thorax. 1990;  45 740-742
  PubMedGoogle Scholar
• 37 Fergusson R J, Lenney J, McHardy G JR, Crompton G K. The use of the Autohaler® device by patients with severe airflow obstruction.  Eur Resp J. 1991;  4 172-174
  PubMedGoogle Scholar
• 38 Ferin J, Mercer T T, Leach L J. The effect of aerosol charge on the deposition and clearance of TiO₂ particles in rats.  Environ Res. 1983;  31 148-151
  CrossrefPubMedGoogle Scholar
• 39 Ferron G A, Oberdörster G, Henneberg R. Estimation of the deposition of aerosolized drugs in the human respiratory tract due to hygroscopic growth.  J Aerosol Med. 1989;  2 271-284
  PubMedGoogle Scholar
• 40 Friegang B. New method of beclometasone aerosol administration to children under 4 years of age.  Can Med Assoc J. 1977;  117 1308-1309
  PubMedGoogle Scholar
• 41 Frieß S, Kutz G. Pulverinhalatoren: vom feindispersen System zum fertigen Arzneimittel.  Dtsch Apoth Ztg. 1993;  133 1242-1245
  PubMedGoogle Scholar
• 42 Gottschalk B, Leupold W, Woller P. Fundamental investigations for the deposition of aerosols from radioactive solutions in the upper and lower airways.  Z Erkr Atmungsorgane. 1979;  153 355-366
  PubMedGoogle Scholar
• 43 Hallworth G W. The formulation and evaluation of pressurized metered-dose inhalers. In: Ganderton D, Jones T (Hrsg). Drug Delivery to the Respiratory Tract Weinheim: VCH 1987: 87-118
  Google Scholar
• 44 Hansen N CG, Eyald T, Ibsen T B. Terbutaline inhalations by the Turbohaler® as replacement for domiciliary nebulizer therapy in severe chronic obstructive pulmonary disease.  Respir Med. 1994;  88 267-271
  PubMedGoogle Scholar
• 45 Heyder J. Deponierung von Aerosolteilchen im Atemtrakt des Menschen. In: Scheuch G. Aerosole in der Inhalationstherapie München: Dustri 1997: 1-10
  Google Scholar
• 46 Heyder J, Gebhart J, Rudolf G, Schiller C F. et al . Deposition of particles in the human respiratory tract in size range 0,005 - 15 µm.  J Aerosol Sci. 1986;  17 811-825
  CrossrefPubMedGoogle Scholar
• 47 Hickey A J, Concessio N M, van Oort M M, Platz R M. Factors influencing the dispersion of dry powders as aerosols.  Pharm Tech. 1994;  8 58-82
  PubMedGoogle Scholar
• 48 Hickey A J, Evans R M. Aerosol generation from propellant-driven MDIs. In: Hichey AJ (Hrsg.). Inhalation Aerosols: Physicals and Biological Basis for Therapy New York: Marcel Dekker 1996: 417-440
  Google Scholar
• 49 Hindle M, Byron P R. Dose emissions from marketed dry powder inhalers.  Int J Pharmaceut. 1995;  116 169-177
  CrossrefPubMedGoogle Scholar
• 50 Holzner P. FCKW-freie Aerosole und Dispergiersysteme. In: Müller RH, Hildebrand GE (Hrsg.). Pharmazeutische Technologie - Moderne Arzneiformen Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH 1996: 31-36
  Google Scholar
• 51 Holzner P. Pharmazeutische Aerosole: Methoden zur Erzeugung, Charakterisierung und Bewertung (Dissertation). Kiel: Christian-Albrechts-Universität Kiel 1995
  Google Scholar
• 52 Holzner P, Müller B W. An in vitro evaluation of various spacer devices for metered dose inhalers using the twin impinger.  Int J Pharm. 1994;  106 69-75
  CrossrefPubMedGoogle Scholar
• 53 Ip A Y, Arakawa T, Silvers H, Ransone C M, Niven R W. Stability of recombinant consensus interferon to air-jet and ultrasonic nebulisation.  J Pharm Sci. 1995;  84 1210-1214
  PubMedGoogle Scholar
• 54 Janssens H M, Devadason S G, Hop W CJ. et al . Varibility of aerosol delivery via spacer devices in young children in daily life.  Eur Respir J. 1999;  13 787-791
  CrossrefPubMedGoogle Scholar
• 55 June D. Achieving the change: challenges and successes in the formulation of CFC-free MDI's.  Eur Respir Rev. 1997;  7 32-34
  PubMedGoogle Scholar
• 56 Kim C S, Trujillo D, Sackner M A. Size aspects of metered-dose inhaler aerosols.  Am Rev Respir Dis. 1985;  132 137-142
  PubMedGoogle Scholar
• 57 Knoch M, Sommer E. Jet nebulizer design and function.  Eur Respir Rev. 2000;  10 (Rev. 72) 183-186
  PubMedGoogle Scholar
• 58 Knoch M, Wunderlich E, Geldner S. A nebulizer system for highly reproducible aerosol delivery.  J Aerosol Med. 1994;  7 229-237
  PubMedGoogle Scholar
• 59 Köhler D. Aerosols for systemic treatment.  Lung. 1990;  168 (Suppl.) 677-684 (Review)
  PubMedGoogle Scholar
• 60 Köhler D. Systemic therapy with aerosols. In: Moran F, Dolovich MB, Newhouse MT, Newman SP (Hrsg.). Aerosols in Medicine Amsterdam: Elsevier Sci 1993: 303-319
  Google Scholar
• 61 Köhler D. Wirksamkeit und Akzeptanz von Pulverinhalatoren.  Dtsch Med Wochenschr. 1995;  120 1401-1404
  PubMedGoogle Scholar
• 62 Köhler D, Grossmann J, Schümichen C, Vastag E, Matthys H. Comparing efficacy of various adrenergic MDIs with the recommended expander systems.  Bull Europ Physiopath Resp. 1986;  22 662s
  PubMedGoogle Scholar
• 63 Köhler D, Simonides R, Rothfuss J, Vastag E, Daikeler G, Matthys H. Aerosolverteilungsmuster von 16 handelsüblichen Aerosolgeräten.  Prax Klin Pneumol. 1983;  37 (Suppl. 1) 922-924
  PubMedGoogle Scholar
• 64 Köhler D, Fleischer W, Matthys H. Depositionsmuster von Dosieraerosolen im menschlichen Organismus.  Atemw Lungenkrkh. 1985;  11 340-341
  PubMedGoogle Scholar
• 65 Köhler D, Fleischer W. Theorie und Praxis der Inhalationstherapie. München: Arcis 2000
  Google Scholar
• 66 Leach C L. Approaches and challenges to use freon propellant replacements.  Aerosol Sci Technol. 1995;  22 329-334
  PubMedGoogle Scholar
• 67 Leach C L. Enhanced drug delivery through reformulating MDIs with HFA propellant-drug deposition and its effect on preclinical and clinical programs. In: Dalby RN, Byron PR, Farr SJ (Hrsg.). Respiratory Drug Delivery V Buffalo Grove: Interpharm Press 1996: 133-144
  Google Scholar
• 68 Marshik P L. et al . A novel breath actuated device (Autohaler®) consistently actuates during the early phase of inspiration.  J Aerosol Med. 1995;  8 187-195
  PubMedGoogle Scholar
• 69 Martonen T B, Katz I. Deposition mechanics of pharmaceutical particles in human airways. In: Hichey AJ (Hrsg). Inhalation Aerosols: Physical and Biological Basis for Therapy New York: Marcel Dekker 1996: 3-28
  Google Scholar
• 70 Martonen T B, Katz I. Deposition patterns of aerosolized drugs within human lungs: effects of ventilatory parameters.  Pharm Res. 1993;  10 871-878
  CrossrefPubMedGoogle Scholar
• 71 Melandri C, Prodi V, Tarroni G, Formignani M, De Zaiacomo T, Bompane G F, Maestri G. On the deposition of unipolarly charged particles in the human respiratory tract.  Inhaled Part Pt. 1975;  1 193-201
  PubMedGoogle Scholar
• 72 Merkus P J, van Essen-Zandfliet E E, Parlevliet E, Borsboom G, Sterk P J, Kerrebijn K F, Quanjer P H. Changes of nebulizer output over the years.  Eur Respir J. 1992;  5 448-491
  PubMedGoogle Scholar
• 73 Morrow-Brown H, Storey G, George W HS. Beclomethasone dipropionate: a new steroid aerosol for the treatment of allergic asthma.  BMJ. 1972;  2 585-590
  PubMedGoogle Scholar
• 74 Nana A, Youngchaiyud P, Maranetra N, Boe J, Löfdahl C.-G, Selroos O, Ståhl E. β₂-agonists administered by a dry powder inhaler can be used in acute asthma.  Respir Med. 1998;  92 167-172
  PubMedGoogle Scholar
• 75 Newhouse M T. Aerosolerzeugung und Verteilungssysteme zur pulmonalen Medikamentenapplikation: Theorie und Praxis.  Innere Medizin. 1993;  48 363-368
  PubMedGoogle Scholar
• 76 Newman S A, Morén F, Pavia D, Little F. et al . Deposition of pressurized suspension aerosols inhaled through extension devices.  Am Rev Respir Dis. 1981;  124 17-20
  PubMedGoogle Scholar
• 77 Newman S P, Hollingworth A, Clark A R. Effect of different modes of inhalation on drug delivery from a dry powder inhaler.  Int J Pharm. 1994;  102 127-132
  CrossrefPubMedGoogle Scholar
• 78 Newman S P, Millar A B, Lennard-Jones T R, Morén F. et al . Improvement of pressurized aerosol deposition with the nebuhaler spacer device.  Thorax. 1984;  39 935-941
  CrossrefPubMedGoogle Scholar
• 79 Newman S P, Weisz A WB, Talaee N, Clarke S W. Improvement of drug delivery with a breath actuated pressurized aerosol for patients with poor inhaler technique.  Thorax. 1991;  46 712-716
  CrossrefPubMedGoogle Scholar
• 80 Newman S P, Morén F, Trofast E, Talaee N. et al . Terbutaline sulphate turbohaler: effect of inhaled flow rate on drug deposition and efficacy.  Int J Pharm. 1991;  74 209-213
  CrossrefPubMedGoogle Scholar
• 81 Newman S P, Morén F, Trofast E, Talaee N, Clarke S W. Deposition and clinical efficacy of terbutaline sulphate from Turbohaler, a new multi-dose powder inhaler.  Eur Respir J. 1989;  2 247-252
  PubMedGoogle Scholar
• 82 Newman S P, Newhouse M T. Effect of add-on devices for aerosol drug delivery: deposition studies and clinical aspects.  J Aerosol Med. 1996;  9 55-70
  PubMedGoogle Scholar
• 83 Nides M A, Tashkin D P, Simmons M S. et al . Improving inhaler adherence in a clinical trial through the use of a nebulizer chronolog.  Chest. 1993;  104 1332-1337
  PubMedGoogle Scholar
• 84 Nikander K. Drug delivery systems.  J Aerosol Med. 1994;  7 S19-24
  PubMedGoogle Scholar
• 85 Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebuliser proved inefficient in nebulising a suspension.  J Aerosol Med. 1999;  12 (Suppl. 2) 47-53
  PubMedGoogle Scholar
• 86 Niven R W, Ip A Y, Mittelman S, Prestrelski S J, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins.  Pharm Res. 1995;  12 53-59
  CrossrefPubMedGoogle Scholar
• 87 O'Callaghan C, Cant M, Robertson C. Delivery of beclomethasone dipropionate from a spacer device: what dose is available for inhalation?.  Thorax. 1994;  49 961-964
  PubMedGoogle Scholar
• 88 O'Callaghan C, Lynch J, Cant M, Robertson C. Improvement in sodium cromoglycate delivery from a spacer device by use of an antistatic lining, immediate inhalation, and avoiding multiple actuation of drug.  Thorax. 1993;  48 603-606
  PubMedGoogle Scholar
• 89 O'Driscoll R. Review of methodology and development of UK nebulizer guidelines (1997) prepared by the British Thoracic Society.  Eur Respir Rev. 2000;  10 (Rev. 72) 203-205
  PubMedGoogle Scholar
• 90 Olsson B, Asking L. Critical aspects of the function of inspiratory flow driven inhalers.  J Aerosol Med. 1994;  7 (Suppl. 1) 43-47
  PubMedGoogle Scholar
• 91 van der Palen J. Multiple inhalers confuse asthma patients.  Eur Respir J. 1999;  14 1034-1037
  CrossrefPubMedGoogle Scholar
• 92 Partridge M R, Woodcock A, Sheffler A L. et al . Chlorofluorocarbon-free inhalers: are we ready for the change?.  Eur Respir J. 1998;  11 1006-1008
  CrossrefPubMedGoogle Scholar
• 93 Patton J S, Bukar J, Nagarajan S. Inhaled insulin.  Adv Drug Deliv Rev. 1999;  35 235-247
  CrossrefPubMedGoogle Scholar
• 94 Pedersen S. How to use a rotahaler.  Arch Dis Child. 1986;  61 11-14
  PubMedGoogle Scholar
• 95 Petro W, Gebert P, Lauber B. Ursachen fehlerhafter Anwendung von Dosieraerosolen.  Pneumologie. 1994;  48 191-196
  PubMedGoogle Scholar
• 96 Pierart F, Wildhaber J H, Vrancken I, Devadason S G, Le Souef P N. Washing plastic spacers in household detergent reduces electrostatic charge and greatly improves delivery.  Eur Respir J. 1999;  13 673-678
  CrossrefPubMedGoogle Scholar
• 97 Ross D L, Schultz R K. Effect on inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products.  J Aerosol Med. 1996;  9 215-226
  PubMedGoogle Scholar
• 98 Sackner M A, Chong C S. Auxiliary MDI aerosol delivery systems.  Chest. 1985;  88 161-169
  PubMedGoogle Scholar
• 99 Sakula A. A history of asthma.  J R Coll Physicians Lond. 1988;  22 36-44
  PubMedGoogle Scholar
• 100 Saunders K B. Misuse of inhaled bronchodilator agents.  BMJ. 1965;  1 1037-1038
  PubMedGoogle Scholar
• 101 Self T H, Rumbak M J, Kelso T M. Correct use of metered-dose inhalers and spacer devices.  Postgrad Med. 1992;  92 95-106
  PubMedGoogle Scholar
• 102 Shim C. Spacer disuse.  Am J Respir Crit Care Med. 2000;  161 A320
  PubMedGoogle Scholar
• 103 Smith E C, Denyer J, Kendrick A H. Comparison of twenty three nebulizer/compressor combinations for domiciliary use.  Eur Respir J. 1995;  8 1214-1221
  CrossrefPubMedGoogle Scholar
• 104 Smith K J, Chan H.-K, Brown K F. Influence of flow rate on aerosol particle size distributions from pressurized and breath-actuated inhalers.  J Aerosol Med. 1998;  11 231-245
  PubMedGoogle Scholar
• 105 Stahlhofen W, Gebhardt J, Heyder J. Experimental determination of the regional deposition of aerosol particles in the human respiratory tract.  Am Ind Hyg Assoc J. 1980;  41 385-397
  PubMedGoogle Scholar
• 106 Svartengren K, Lindestad P.-A, Svartengren M, Philipson K, Bylin G, Cammer P. Added external resistance reduces oropharyngeal deposition and increases lung deposition of aerosol particles in asthmatics.  Am J Respir Crit Care Med. 1995;  152 32-37
  PubMedGoogle Scholar
• 107 Tang I N, Munkelwitz H R, Davis J G. Aerosol growth studies. III.  J Aerosol Sci. 1977;  8 321-330
  PubMedGoogle Scholar
• 108 The COPD guidelines group of the standards of care committee of the BTS . BTS guidelines for the management of chronic obstructive pulmonary disease.  Thorax. 1997;  52 (Suppl. 5) 1-28
  PubMedGoogle Scholar
• 109 Thompson J, Irvine T H, Grathwohl K, Roth B. Misuse of metered-dose inhalers in hospitalized patients.  Chest. 1994;  105 715-717
  PubMedGoogle Scholar
• 110 Thorsson L, Edsbacker S. Lung deposition from a pressurised metered dose inhaler attached to a spacer.  Eur Respir J. 1998;  12 1340-1345
  CrossrefPubMedGoogle Scholar
• 111 Tiano S L, Dalby R N. Comparison of a respiratory suspension aerosolized by an airjet and an ultrasonic nebuliser.  Pharm Dev Technol. 1996;  1 261-268
  PubMedGoogle Scholar
• 112 Vidgen M T, Patronen T P, Kärkkäinen A, Karjalainen P. Effect of extension devices on the drug deposition from inhalation aerosols.  Int J Parm. 1987;  39 107-112
  PubMedGoogle Scholar
• 113 Visser J. Van der Waals and other cohesive forces affecting powder fluidization.  Powder Technol. 1989;  58 1-10
  PubMedGoogle Scholar
• 114 Webb J, Rees J, Clark T J. A comparison of the effects of different methods of administration of beta 2 sympathomimetics in patients with asthma.  Br J Dis Chest. 1982;  76 351-357
  CrossrefPubMedGoogle Scholar
• 115 Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, Smith A. Effect of nebuliser type and antibiotic concentration on device performances.  Pediatr Pulmonol. 1997;  23 249-260
  CrossrefPubMedGoogle Scholar
• 116 Wettengel R, Berdel D, Hoffmann D, Krause J, Kroegel C, Kroidl R F, Leupold W, Lindemann H, Magnussen H, Meister R, Moor H, Nolte D, Rabe K F, Reinhardt D, Sauer R, Schultze-Werninghaus G, Ukena D, Worth H. Asthmatherapie bei Kindern und Erwachsenen. Empfehlungen der Deutschen Atemwegsliga in der Deutschen Gesellschaft für Pneumologie.  Med Klin. 1998;  93 639-650
  PubMedGoogle Scholar
• 117 Wetterlin K. Turbohaler: a new powder inhaler for administration of drugs to the airways.  Pharm Res. 1988;  5 506-508
  CrossrefPubMedGoogle Scholar
• 118 Wigley F W, Londono J H, Wood S H, Shipp J C, Waldman R H. Insulin across respiratory mucosae by aerosol delivery.  Diabetes. 1971;  20 552-556
  PubMedGoogle Scholar
• 119 Wildhaber J H, Devadason S G, Hayden M J, James R, Dufty A P, Fox R A, Summers Q A, Le Souef P N. Electrostatic charge on a plastic spacer device influences the delivery of salbutamol.  Eur Respir J. 1996;  9 1943-1946
  CrossrefPubMedGoogle Scholar
• 120 Winsel K, Bergmann K C, Lachmann B. Untersuchungen über die Ultraschallverneblung von oberflächenaktiven Stoffen aus Lungengewebe und Lecithin-Dispersionen im Hinblick auf die künstliche Befilmung von Lungen.  Z Erkr Atmungsorgane. 1974;  140 151-158
  PubMedGoogle Scholar
• 121 Zanen P, van Spiegel P I, van der Kolk H, Tushuisen E. et al . The effect of the inhalation flow on the performance of a dry powder inhalation system.  Int J Pharm. 1992;  81 199-203
  CrossrefPubMedGoogle Scholar

Dr. Th. Voshaar

Krankenhaus Bethanien

Bethanienstr. 21

47441 Moers